A Study to Learn More About Copanlisib Treatment Patterns in People With Indolent Non-Hodgkin Lymphoma, a Type of Cancer That Grows and Spread Slowly and Develops in the Lymphatic System (a Part of Immune System) in Taiwan Under Real-word Conditions

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

August 31, 2024

Study Completion Date

August 31, 2024

Conditions

Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Interventions

DRUG

Copanlisib (BAY80-6946)

Copanlisib for treatment of relapse/refractory (r/r) indolent non-Hodgkin lymphoma (iNHL)

Trial Locations (1)

Many Locations, Multiple Locations